Mechlorethamine
- Generic Name
- Mechlorethamine
- Brand Names
- Valchlor, Ledaga
- Drug Type
- Small Molecule
- Chemical Formula
- C5H11Cl2N
- CAS Number
- 51-75-2
- Unique Ingredient Identifier
- 50D9XSG0VR
- Background
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage.
...
- Indication
For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
- Associated Conditions
- Bronchogenic Carcinoma, Chronic Lymphocytic Leukemia, Hodgkins Disease (HD), Lymphoma, Diffuse, Mycosis Fungoides (MF), Polycythemia Vera (PV), Stage I Mycosis Fungoides, Malignant effusion
- Associated Therapies
- -
Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Centre for Human Drug Research, Netherlands
- Target Recruit Count
- 32
- Registration Number
- NCT05303480
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT05106192
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Effect of Vitamin D After Application With Valchlor
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT02968446
- Locations
- 🇺🇸
University Hospitals, Cleveland, Ohio, United States
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02296164
- Locations
- 🇺🇸
Investigator Site, Fairfax, Virginia, United States
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT00352027
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 854
- Registration Number
- NCT00003389
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.